| Generic name | Bosutinib |
| Pronunciation | boe-SUE-ti-nib |
| Brand name(s), other common name(s) | Bosulif® |
| Drug type | Tyrosine kinase inhibitor (TKI) |
| How the drug is given | By Mouth |
Indications and Usage
Bosutinib is FDA approved for the treatment of adult patients with
- Chronic, accelerated, or blast phase Ph+ chronic myeloid leukemia (CML) with resistance or intolerance to prior therapy.
- Newly-diagnosed chronic phase Ph+ chronic myeloid leukemia (CML). This indication is approved under accelerated approval based on molecular and cytogenetic response rates. Continued approval for this indication may be contingent upon verification and confirmation of clinical benefit in an ongoing long-term follow up trial.
Side effects needing medical attention
Diarrhea; nausea; vomiting; abdominal pain; low blood cell counts; rash; anemia; fever; fatigue; headache; dizziness; cough; anaphylactic shock; myelosuppression; fluid retention; liver damage; rash.
For information on how to manage the costs of drug therapy, please see Financial Support, or to speak with an Information Specialist, call (800) 955-4572.